Clinical Trial Update: Trial to Assess the Efficacy of F598 in Preventing an Experimental Urethral Infection With N. Gonorrhoeae in Healthy Males [Phase 2]

View source ↗

Summary

A Phase 2 trial assessing the efficacy of F598 to prevent experimental urethral infection with Neisseria gonorrhoeae in healthy males has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gonorrhea

Drugs mentioned

• F598

Snippet

Sponsor: Alopexx Pharmaceuticals, LLC | Conditions: Neisseria Gonorrhoeae | Phase 2 | Status: TERMINATED